Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
ScripVenture capital investment in the biopharmaceutical industry is on an undeniable upswing, with two quarters in a row of fundraising in 2024 that outpace the activity seen in 2023, according to data fr
ScripAltruBio Inc. took a big step up from its $63m series A venture capital round in 2021 when it announced a series B round totaling up to $225m on 21 May, which will fund ongoing and planned Phase IIa
ScripConditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio